La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The genetics of Parkinson's disease: Progress and therapeutic implications

Identifieur interne : 000F19 ( Main/Exploration ); précédent : 000F18; suivant : 000F20

The genetics of Parkinson's disease: Progress and therapeutic implications

Auteurs : Andrew B. Singleton [États-Unis] ; Matthew J. Farrer [Canada] ; Vincenzo Bonifati [Pays-Bas]

Source :

RBID : ISTEX:1897BB23048D40AB2FDCC914B29DCA3B9F6AD5AC

Abstract

The past 15 years has witnessed tremendous progress in our understanding of the genetic basis for Parkinson's disease (PD). Notably, whereas most mutations, such as those in SNCA, PINK1, PARK2, PARK7, PLA2G6, FBXO7, and ATP13A2, are a rare cause of disease, one particular mutation in LRRK2 has been found to be common in certain populations. There has been considerable progress in finding risk loci. To date, approximately 16 such loci exist; notably, some of these overlap with the genes known to contain disease‐causing mutations. The identification of risk alleles has relied mostly on the application of revolutionary technologies; likewise, second‐generation sequencing methods have facilitated the identification of new mutations in PD. These methods will continue to provide novel insights into PD. The utility of genetics in therapeutics relies primarily on leveraging findings to understand the pathogenesis of PD. Much of the investigation into the biology underlying PD has used these findings to define a pathway, or pathways, to pathogenesis by trying to fit disparate genetic defects onto the same network. This work has had some success, particularly in the context of monogenic disease, and is beginning to provide clues about potential therapeutic targets. Approaches toward therapies are also being provided more directly by genetics, notably by the reduction and clearance of alpha‐synuclein and inhibition of Lrrk2 kinase activity. We believe this has been an exciting, productive time for PD genetics and, furthermore, that genetics will continue to drive the etiologic understanding and etiology‐based therapeutic approaches in this disease. © 2013 Movement Disorder Society

Url:
DOI: 10.1002/mds.25249


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The genetics of Parkinson's disease: Progress and therapeutic implications</title>
<author>
<name sortKey="Singleton, Andrew B" sort="Singleton, Andrew B" uniqKey="Singleton A" first="Andrew B." last="Singleton">Andrew B. Singleton</name>
</author>
<author>
<name sortKey="Farrer, Matthew J" sort="Farrer, Matthew J" uniqKey="Farrer M" first="Matthew J." last="Farrer">Matthew J. Farrer</name>
</author>
<author>
<name sortKey="Bonifati, Vincenzo" sort="Bonifati, Vincenzo" uniqKey="Bonifati V" first="Vincenzo" last="Bonifati">Vincenzo Bonifati</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1897BB23048D40AB2FDCC914B29DCA3B9F6AD5AC</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1002/mds.25249</idno>
<idno type="url">https://api-v5.istex.fr/document/1897BB23048D40AB2FDCC914B29DCA3B9F6AD5AC/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000602</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000602</idno>
<idno type="wicri:Area/Istex/Curation">000602</idno>
<idno type="wicri:Area/Istex/Checkpoint">000037</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000037</idno>
<idno type="wicri:doubleKey">0885-3185:2013:Singleton A:the:genetics:of</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578399</idno>
<idno type="RBID">PMC:3578399</idno>
<idno type="wicri:Area/Pmc/Corpus">000833</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000833</idno>
<idno type="wicri:Area/Pmc/Curation">000833</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000833</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000566</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000566</idno>
<idno type="wicri:Area/Ncbi/Merge">001382</idno>
<idno type="wicri:Area/Ncbi/Curation">001382</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001382</idno>
<idno type="wicri:doubleKey">0885-3185:2013:Singleton A:the:genetics:of</idno>
<idno type="wicri:Area/Main/Merge">000F31</idno>
<idno type="wicri:Area/Main/Curation">000F19</idno>
<idno type="wicri:Area/Main/Exploration">000F19</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">The genetics of Parkinson's disease: Progress and therapeutic implications</title>
<author>
<name sortKey="Singleton, Andrew B" sort="Singleton, Andrew B" uniqKey="Singleton A" first="Andrew B." last="Singleton">Andrew B. Singleton</name>
<affiliation wicri:level="1">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Maryland, Bethesda</wicri:regionArea>
<wicri:noRegion>Bethesda</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author>
<name sortKey="Farrer, Matthew J" sort="Farrer, Matthew J" uniqKey="Farrer M" first="Matthew J." last="Farrer">Matthew J. Farrer</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medical Genetics, University of British Columbia, Vancouver</wicri:regionArea>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Bonifati, Vincenzo" sort="Bonifati, Vincenzo" uniqKey="Bonifati V" first="Vincenzo" last="Bonifati">Vincenzo Bonifati</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical Genetics, Rotterdam, Erasmus MC</wicri:regionArea>
<wicri:noRegion>Erasmus MC</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov Disord</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Blackwell Publishing Ltd</publisher>
<date type="published" when="2013-01">2013-01</date>
<biblScope unit="volume">28</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="14">14</biblScope>
<biblScope unit="page" to="23">23</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1897BB23048D40AB2FDCC914B29DCA3B9F6AD5AC</idno>
<idno type="DOI">10.1002/mds.25249</idno>
<idno type="ArticleID">MDS25249</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">The past 15 years has witnessed tremendous progress in our understanding of the genetic basis for Parkinson's disease (PD). Notably, whereas most mutations, such as those in SNCA, PINK1, PARK2, PARK7, PLA2G6, FBXO7, and ATP13A2, are a rare cause of disease, one particular mutation in LRRK2 has been found to be common in certain populations. There has been considerable progress in finding risk loci. To date, approximately 16 such loci exist; notably, some of these overlap with the genes known to contain disease‐causing mutations. The identification of risk alleles has relied mostly on the application of revolutionary technologies; likewise, second‐generation sequencing methods have facilitated the identification of new mutations in PD. These methods will continue to provide novel insights into PD. The utility of genetics in therapeutics relies primarily on leveraging findings to understand the pathogenesis of PD. Much of the investigation into the biology underlying PD has used these findings to define a pathway, or pathways, to pathogenesis by trying to fit disparate genetic defects onto the same network. This work has had some success, particularly in the context of monogenic disease, and is beginning to provide clues about potential therapeutic targets. Approaches toward therapies are also being provided more directly by genetics, notably by the reduction and clearance of alpha‐synuclein and inhibition of Lrrk2 kinase activity. We believe this has been an exciting, productive time for PD genetics and, furthermore, that genetics will continue to drive the etiologic understanding and etiology‐based therapeutic approaches in this disease. © 2013 Movement Disorder Society</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
<li>Pays-Bas</li>
<li>États-Unis</li>
</country>
</list>
<tree>
<country name="États-Unis">
<noRegion>
<name sortKey="Singleton, Andrew B" sort="Singleton, Andrew B" uniqKey="Singleton A" first="Andrew B." last="Singleton">Andrew B. Singleton</name>
</noRegion>
</country>
<country name="Canada">
<noRegion>
<name sortKey="Farrer, Matthew J" sort="Farrer, Matthew J" uniqKey="Farrer M" first="Matthew J." last="Farrer">Matthew J. Farrer</name>
</noRegion>
</country>
<country name="Pays-Bas">
<noRegion>
<name sortKey="Bonifati, Vincenzo" sort="Bonifati, Vincenzo" uniqKey="Bonifati V" first="Vincenzo" last="Bonifati">Vincenzo Bonifati</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F19 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F19 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:1897BB23048D40AB2FDCC914B29DCA3B9F6AD5AC
   |texte=   The genetics of Parkinson's disease: Progress and therapeutic implications
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022